$17.92
▲ +1.0% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
AMRX: Raising target price to $19.00
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
3 Reasons AMRX is Risky and 1 Stock to Buy Instead
Overview
52-week range
$7.07
$15
100% of range
Avg surprise (last 2)
+35.5%
Avg reaction (last 1)
+3.0%
100% positive
Latest IV / EM
89%
EM ±20.4% · $18 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $0.19 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $0.01 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $0.23 | $0.17 | +35.3% | — | — | earnings |
| Fri May 2, 2025 | Mar/2025 | $0.19 | $0.14 | +35.7% | — | +3.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | — | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.02 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.30 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.06 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.08 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | BMO | $0.24 | $0.23 | +4.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $402M | — | $511M | $438M | $440M | — | $433M | $452M |
| Gross profit | $320M | — | $274M | $286M | $256M | — | $270M | $250M |
| Operating income | $142M | — | $70M | $111M | $100M | — | $89M | $95M |
| Net income | $62M | — | $2M | $22M | $12M | — | $-156,000 | $6M |
| EPS (diluted) | $0.19 | — | $0.01 | $0.07 | $0.04 | — | — | $0.02 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $198M | $282M | $201M | $72M | $59M | $111M | $74M | $44M |
| Inventory | $642M | $606M | $614M | $609M | $601M | $612M | $596M | $576M |
| Total current assets | $1.80B | $1.91B | $1.84B | $1.58B | $1.51B | $1.59B | $1.51B | $1.49B |
| Total assets | $3.54B | $3.68B | $3.60B | $3.42B | $3.37B | $3.50B | $3.46B | $3.51B |
| Long-term debt | $2.57B | $2.57B | $2.57B | $2.15B | $2.15B | $2.16B | $2.17B | $2.18B |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $-45M | $-71M | $-109M | $-112M | $-132M | $-109M | $-93M | $-57M |